(Q37634765)

21 August 2017

1 reference

title

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors (English)

1 reference

21 August 2017

Erin E Mancl

1

1 reference

21 August 2017

Jill M Kolesar

series ordinal

2

1 reference

21 August 2017

Lee C Vermeulen

series ordinal

3

1 reference

21 August 2017

publication date

1 December 2009

1 reference

American Journal of Health-System Pharmacy

21 August 2017

published in

1 reference

21 August 2017

volume

66

1 reference

21 August 2017

issue

23

1 reference

21 August 2017

page(s)

2105-2112

1 reference

Cetuximab for the treatment of colorectal cancer.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

KRAS mutations predict response to EGFR inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Epidermal growth factor receptor: mechanisms of activation and signalling.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090036

31 March 2020

Identifiers

DOI

10.2146/AJHP090036

1 reference

21 August 2017

1 reference